Increased Mortality Risk for Melanoma in Situ Patients, Though Survival Rate Higher Than General Population

Source: HCP Live, June 2023

This new research indicates substantial detection of lower-risk disease among patients who are considered to be health-seeking.

Patients with a melanoma in situ (MIS) diagnosis have an increased but still low risk of melanoma-specific death and live longer than those in the general population, new findings suggest, indicating substantial low-risk disease detection among health-seeking patients.

These findings were explored given that, although there is increasing frequency of MIS diagnosis, very little data exists regarding its link with melanoma-specific or all-cause mortality.2 Knowing the risk for mortality among those with MIS was seen as important for provision of information to identify specific subgroups that may be at higher risk of dying.